AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20032539 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/emtricitabine/efavirenz (n=17)
Number of subjects: 32
Study 20032539 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative matched controls (n=15)
Number of subjects: 32
Study 16717120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2.5, 5, 7.5, and 10 microg/kg per minute)
Number of subjects: 60
Study 16717120 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.125, 0.250, 0.375, and 0.5 microg/kg per minute)
Number of subjects: 60
Study 16717120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine and Epinephrine (both groups)
Number of subjects: 60
Study 15168020 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 g t10c12CLA for 12 weeks
Number of subjects: 57
Study 15168020 — intervention group
Group type: COMPARATOR
Intervention: Control oil for 12 weeks
Number of subjects: 57
Study 11331320 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 2,600 mg/m2 by 24‐hour infusion, weekly
Number of subjects: 1120
Study 11331320 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐phosphonoacetyl‐l‐aspartic acid 250 mg/m2 day 1, 5‐FU 2,600 mg/m2 by 24‐hour infusion day 2, weekly
Number of subjects: 1120
Study 11331320 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 600 mg/m2 with oral leucovorin (LV) 125 mg/m2 hourly for the preceding 4 hours, weekly
Number of subjects: 1120
Study 11331320 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 600 mg/m2 with intravenous (IV) LV 600 mg/m2, weekly
Number of subjects: 1120
Study 11331320 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 750 mg/m2/d IV by continuous infusion for 5 days, then 750 mg/m2 weekly, and recombinant interferon alfa‐2a 9 million units subcutaneously three times weekly
Number of subjects: 1120
Study 11331320 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU as a 24‐hour infusion weekly (control group)
Number of subjects: 1120
Study 9223392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide infusion in insulin-treated patients
Number of subjects: 24
Study 9223392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide infusion in diet/oral hypoglycaemic agents-treated patients
Number of subjects: 24
Study 9223392 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 7964336 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters of childhood leukaemias
Number of subjects: 9406
Study 7964336 — intervention group
Group type: COMPARATOR
Intervention: Non-clustered cases
Number of subjects: 9406
Study 3555838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (40 mg three times daily)
Number of subjects: 43
Study 3555838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen (0.5 mg three times daily)
Number of subjects: 43
Study 3555838 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine
Number of subjects: 43
Study 3555838 — intervention group
Group type: COMPARATOR
Intervention: Pizotifen
Number of subjects: 43
Study 31922456 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal research language
Number of subjects: 303
Study 31922456 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal language about research support
Number of subjects: 303
Study 31922456 — intervention group
Group type: COMPARATOR
Intervention: No information about research (Control)
Number of subjects: 303
Study 29801444 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Promotion (MBHP)
Number of subjects: 160
Study 29801444 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 160
Study 28804048 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 45 minutes
Number of subjects: 20
Study 28804048 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent resistance and aerobic exercise for 45 minutes
Number of subjects: 20
Study 28804048 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exercise session at seated rest)
Number of subjects: 20
Study 25068452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention group
Number of subjects: 240
Study 25068452 — intervention group
Group type: COMPARATOR
Intervention: 1-day psycho-educational control group
Number of subjects: 240
Study 22435369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.1 mg/kg or 0.25 mg/kg)
Number of subjects: 75
Study 22435369 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 75
Study 22435369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg)
Number of subjects: 75
Study 21111307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis ZA9003 aspheric IOL
Number of subjects: 65
Study 21111307 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-1 VA-60BB spherical IOL
Number of subjects: 65
Study 21111307 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SA60AT spherical IOL
Number of subjects: 65
Study 18202419 — intervention group
Group type: COMPARATOR
Intervention: CISCA/VB (cyclophosphamide 400 mg/m(2) d1-2, doxorubicin 35 mg/m(2) d1-2, cisplatin 100 mg/m(2) d3/vinblastine 2.5 mg/m(2) d1-5)
Number of subjects: 190
Study 18202419 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP (bleomycin 30 mg d1, d8, d15; etoposide 100 mg/m(2) d1-5; cisplatin 20 mg/m(2) d1-5)
Number of subjects: 190
Study 18202419 — intervention group
Group type: COMPARATOR
Intervention: CISCA/VB
Number of subjects: 190
Study 18202419 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP
Number of subjects: 190
Study 15904616 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 122
Study 15904616 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 122
Study 12885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine consumption
Number of subjects: 1196
Study 12885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer consumption
Number of subjects: 1196
Study 12885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirits consumption
Number of subjects: 1196
Study 12885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer consumption in wine drinkers
Number of subjects: 1196
Study 12885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer consumption in non-wine drinkers
Number of subjects: 1196
Study 10566562 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 272
Study 10566562 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 272
Study 10566562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 272
Study 10566562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 8739864 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-antagonist (terfenadine)
Number of subjects: 12
Study 8739864 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-antagonist (cimetidine)
Number of subjects: 12
Study 8739864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of H1 and H2 antagonists
Number of subjects: 12
Study 8739864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1816109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zidovudine 250 mg twice daily combined with oral acyclovir 800 mg twice daily
Number of subjects: 16
Study 1816109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zidovudine 250 mg twice daily combined with lymphoblastoid interferon‐alpha 1.5 x 10(6) IU administered subcutaneously three times weekly
Number of subjects: 16
Study 1816109 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 16
Study 6312008 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH (20 to 30 units/day)
Number of subjects: 24
Study 6312008 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (2 mg/kg/day)
Number of subjects: 24
Study 6312008 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 24
Study 6312008 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH and Prednisone
Number of subjects: 24
Study 6312008 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 24
Study 31856714 — intervention group
Group type: EXPERIMENTAL
Intervention: CORIN SNPs (rs2289433, rs6823184, rs10517195, rs2271037, rs12509275)
Number of subjects: 1462
Study 31856714 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs6823184 and linked SNPs (rs10049713, rs6823698, rs1866689)
Number of subjects: 1462
Study 31856714 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs6823184
Number of subjects: 1462
Study 31856714 — intervention group
Group type: EXPERIMENTAL
Intervention: cg02955940 methylation
Number of subjects: 1462
Study 27936374 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitation (TSF)
Number of subjects: 267
Study 27936374 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 267
Study 27936374 — intervention group
Group type: COMPARATOR
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 267
Study 27936374 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 267
Study 26346805 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Surgery within 12 hours
Number of subjects: 170
Study 26346805 — intervention group
Group type: COMPARATOR
Intervention: Initial Conservative Treatment
Number of subjects: 170
Study 26346805 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Surgery
Number of subjects: 170
Study 25852045 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Education in Victorian Schools program (intervention group, n=1,163)
Number of subjects: 1752
Study 25852045 — intervention group
Group type: COMPARATOR
Intervention: Usual drug education program (control group, n=589)
Number of subjects: 1752
Study 22946452 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage group (1-hour Swedish massage)
Number of subjects: 22
Study 22946452 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 22
Study 20676961 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (n = 31)
Number of subjects: 59
Study 20676961 — intervention group
Group type: COMPARATOR
Intervention: Standard HF treatment (n = 29)
Number of subjects: 59
Study 17376253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipuro propofol with lidocaine
Number of subjects: 328
Study 17376253 — intervention group
Group type: COMPARATOR
Intervention: Lipuro propofol
Number of subjects: 328
Study 17376253 — intervention group
Group type: COMPARATOR
Intervention: Diprivan with lidocaine
Number of subjects: 328
Study 17376253 — intervention group
Group type: COMPARATOR
Intervention: Diprivan propofol
Number of subjects: 328
Study 16305876 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP‐induced pulsatile (automatic 80 bpm) CPB (group B)
Number of subjects: 40
Study 16305876 — intervention group
Group type: COMPARATOR
Intervention: Standard nonpulsatile CPB with IABP discontinued during cardioplegic arrest (group A)
Number of subjects: 40
Study 12537406 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting (DS) without predilation
Number of subjects: 60
Study 12537406 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting with predilation (SWP)
Number of subjects: 60
Study 9665104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 523
Study 9665104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 523
Study 7535676 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg twice daily)
Number of subjects: 9
Study 2243982 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler flow imaging
Number of subjects: 30
Study 357764 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide, 40 mg twice daily
Number of subjects: 0
Study 357764 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide, 50 mg twice daily
Number of subjects: 0
Study 30327302 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 184
Study 30327302 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 184
Study 28551048 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal height staples
Number of subjects: 61
Study 28551048 — intervention group
Group type: COMPARATOR
Intervention: Graduated height staples
Number of subjects: 61
Study 26073262 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 36
Study 26073262 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (2mg bid p.o.)
Number of subjects: 36
Study 26073262 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 36
Study 26073262 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 36
Study 22679249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1-4 mg
Number of subjects: 942
Study 22679249 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10-40 mg
Number of subjects: 942
Study 22679249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin low-dose (1 mg)
Number of subjects: 942
Study 22679249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin intermediate-dose (2 mg)
Number of subjects: 942
Study 22679249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin higher-dose (4 mg)
Number of subjects: 942
Study 22679249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin low doses
Number of subjects: 942
Study 22679249 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin low doses
Number of subjects: 942
Study 22679249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin intermediate doses
Number of subjects: 942
Study 22679249 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin intermediate doses
Number of subjects: 942
Study 22679249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin higher doses
Number of subjects: 942
Study 22679249 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin higher doses
Number of subjects: 942
Study 22051734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT) based on clinical (C) and genomic (G) risk assessment
Number of subjects: 800
Study 22051734 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-based chemotherapy
Number of subjects: 800
Study 22051734 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/capecitabine chemotherapy
Number of subjects: 800
Study 22051734 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy with letrozole
Number of subjects: 800
Study 22051734 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy with tamoxifen→letrozole
Number of subjects: 800
Study 19902755 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with acupoint-injection (10 sessions of EA once a day for 10 days, and 5 sessions of acupoint-injection once every two days)
Number of subjects: 60
Study 19902755 — intervention group
Group type: COMPARATOR
Intervention: Single Electroacupuncture (EA) (10 sessions once a day for 10 days)
Number of subjects: 60
Study 16600928 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein from lean red meat
Number of subjects: 60
Study 12570940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycoprotein IIb/IIIa receptor antagonists
Number of subjects: 20137
Study 12570940 — intervention group
Group type: COMPARATOR
Intervention: Heparin infusion continued after the procedure
Number of subjects: 20137
Study 12570940 — intervention group
Group type: COMPARATOR
Intervention: Heparin infusion discontinued after the procedure
Number of subjects: 20137
Study 10807488 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 372
Study 10807488 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 372
Study 10807488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 8738314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 378
Study 8738314 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 378
Study 8738314 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 378
Study 1397716 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 8
Study 3888734 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and insulin
Number of subjects: 202
Study 3888734 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 202
Study 31895283 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg Press
Number of subjects: 19
Study 31895283 — intervention group
Group type: COMPARATOR
Intervention: Free Weights
Number of subjects: 19
Study 31895283 — intervention group
Group type: COMPARATOR
Intervention: Smith Machine
Number of subjects: 19
Study 31895283 — intervention group
Group type: COMPARATOR
Intervention: Squats (Free Weights and Smith Machine)
Number of subjects: 19
Study 29692005 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐05280586
Number of subjects: 185
Study 29652462 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) for decontamination of implant surface
Number of subjects: 52
Study 29652462 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gel (CHX) followed by saline irrigation
Number of subjects: 52
Study 24582046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 15 mg (single dose)
Number of subjects: 192
Study 24582046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg (single dose)
Number of subjects: 192
Study 24582046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg twice daily for 5 days
Number of subjects: 192
Study 22436841 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (T)
Number of subjects: 48
Study 22436841 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-reduced diet (D)
Number of subjects: 48
Study 22436841 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and increased diet (T-iD)
Number of subjects: 48
Study 22436841 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 48
Study 20507600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch patient advocacy case management intervention
Number of subjects: 0
Study 20507600 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18779444 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment recovery measurement in the most affected lead on the post-PCI ECG
Number of subjects: 4866
Study 15727161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertigoheel® (VH)
Number of subjects: 1388
Study 15727161 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (betahistine, Ginkgo biloba extract, dimenhydrinate)
Number of subjects: 1388
Study 15537696 — intervention group
Group type: EXPERIMENTAL
Intervention: miconazole and rifampicin modified catheter (n=118)
Number of subjects: 223
Study 15537696 — intervention group
Group type: COMPARATOR
Intervention: standard triple-lumen CVC (n=105)
Number of subjects: 223
Study 11273927 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive IA Morphine (3 mg)
Number of subjects: 40
Study 11273927 — intervention group
Group type: COMPARATOR
Intervention: Postoperative IA Morphine (3 mg)
Number of subjects: 40
Study 9423805 — intervention group
Group type: EXPERIMENTAL
Intervention: S-nitrosoglutathione (GSNO) 50 microg/min
Number of subjects: 12
Study 9423805 — intervention group
Group type: COMPARATOR
Intervention: Control (no GSNO)
Number of subjects: 12
Study 8491304 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide, 750 mg daily for 2 days before the ascent and on the first day at altitude (3,200 m)
Number of subjects: 16
Study 8491304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acetazolamide)
Number of subjects: 16
Study 8491304 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide group (T)
Number of subjects: 16
Study 8491304 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 16
Study 3022035 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regimen (cyclophosphamide, oncovin, nimustine hydrochloride, procarbazine - CONP) every four weeks
Number of subjects: 69
Study 3022035 — intervention group
Group type: COMPARATOR
Intervention: Alternating regimen (CONP alternating with etoposide, adriamycin, cisplatin - VAD at four-week intervals)
Number of subjects: 69
Study 3022035 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rates
Number of subjects: 69
Study 3022035 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected median survival times
Number of subjects: 69
Study 3022035 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival beyond two years
Number of subjects: 69
Study 3022035 — intervention group
Group type: EXPERIMENTAL
Intervention: Major toxicity
Number of subjects: 69
Study 3022035 — intervention group
Group type: EXPERIMENTAL
Intervention: Death due to treatment
Number of subjects: 69
Study 27393706 — intervention group
Group type: EXPERIMENTAL
Intervention: Student self-assessment
Number of subjects: 0
Study 27393706 — intervention group
Group type: COMPARATOR
Intervention: Faculty assessment
Number of subjects: 0
Study 27030661 — intervention group
Group type: EXPERIMENTAL
Intervention: High expectations of recovery
Number of subjects: 716
Study 27030661 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate expectations of recovery
Number of subjects: 716
Study 27030661 — intervention group
Group type: COMPARATOR
Intervention: Low expectations of recovery
Number of subjects: 716
Study 24213216 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly teriparatide (56.5 μg for 72 weeks)
Number of subjects: 542
Study 24213216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 22695789 — intervention group
Group type: EXPERIMENTAL
Intervention: Community falls prevention service
Number of subjects: 157
Study 22695789 — intervention group
Group type: COMPARATOR
Intervention: Usual health and social care
Number of subjects: 157
Study 20554120 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion at the beginning of the 1st half of the night
Number of subjects: 8
Study 20554120 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion at the beginning of the 2nd half of the night
Number of subjects: 8
Study 20554120 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8